Название продукции:1-(3-bromo-4-ethylphenyl)ethanone
IUPAC Name:1-(3-bromo-4-ethylphenyl)ethan-1-one
- CAS：90841-42-2
- Молекулярная формула：C10H11BrO
- Чистота：95%+
- Номер в каталоге：CM588910
- Молекулярная масса：227.1
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:90841-42-2
- Молекулярная формула:C10H11BrO
- Точка плавления:-
- Smiles-код:CCC1=C(C=C(C=C1)C(=O)C)Br
- Плотность:
- Номер в каталоге:CM588910
- Молекулярная масса:227.1
- Точка кипения:
- Номер Mdl:
- Хранение:
Column Infos
- Alectinib
- Genentech, a member of the Roche Group, has announced that its ALK inhibitor Alecensa® (Alectinib) met its primary endpoint of disease-free survival (DFS) at a scheduled interim analysis of the phase 3 ALINA trial. Alecensa as adjuvant therapy resulted in statistically significant DFS and clinically meaningful improvement.
Worldwide, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases. Despite adjuvant chemotherapy, about half of patients with early-stage lung cancer experience cancer recurrence after surgery. Recent therapeutic innovations, including immunotherapy, have improved the outlook for some patients with early-stage NSCLC; however, there are currently no ALK inhibitors approved for early-stage ALK-positive disease. Alecensa is the first ALK inhibitor proven in a Phase 3 trial to reduce the risk of disease recurrence or death in patients with early-stage ALK-positive NSCLC.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Поиск 
+86 21 5895 0110 
